trending Market Intelligence /marketintelligence/en/news-insights/trending/lsMwwnDwtWFYDk1SVh0k3g2 content esgSubNav
In This List

Biogen board authorizes $5B share buyback program

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Biogen board authorizes $5B share buyback program

Biogen Inc. said its board of directors authorized a program to buy back up to $5 billion of its common stock.

The share repurchase program does not have an expiration date. All share repurchases under the program will be retired.

The current program is in addition to the buyback program authorized by the Cambridge, Mass.-based drugmaker's board in March.

Biogen develops and manufactures therapies for neurological and neurodegenerative diseases.